Paciente gran superviviente con cáncer de cabeza y cuello metastásico y tratamiento con inmunoterapia

  1. Olivares, A. 1
  2. Del Barco, E. 1
  3. Bellido, L. 1
  4. Cigarral, B. 1
  5. Claros, J. 1
  6. Escalera, E. 1
  7. Barrios, B. 1
  8. Casado, D. 1
  9. Figuero, L. 1
  10. López, A. 1
  11. Terán, E. 1
  12. Cruz, J.J. 1
  1. 1 Instituto de Investigación Biomédica de Salamanca (IBSAL), Servicio de Oncología Médica, Complejo Asistencial Universitario de Salamanca (CAUSA), Salamanca, España
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2021

Título del ejemplar: Enfermedades oncológicas (II)Tumores torácicos. Cáncer de cabeza y cuello

Serie: 13

Número: 25

Páginas: 1429-1430

Tipo: Artículo

DOI: 10.1016/J.MED.2021.02.010 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Referencias bibliográficas

  • Iglesias LC, Arrazubi V, Baste N, Carral A, Cirauqui B, Escobar Y, et al. SEOM clinical guidelines for the treatment of head and neck cáncer (2017). Clin Transl Oncol. 2018;20(1):75-83.
  • Pignon JP, Le Maître A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17346 patients. Radiother Oncol. 2009; 92(1):4-14.
  • Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rot-tey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116-27.
  • Hitt R, Grau JJ, López-Pousa A, Berrocal A, García-Girón C, Irigoyen A, et al. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemora-diotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol. 2014;25(1):216-25.
  • Ghi MG, Paccagnella A, Ferrari D, Foa P, Alterio D, Codecá C, et al. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial. Ann Oncol. 2017; 28(9): 2206-12.
  • Hitt R, Irigoyen A, Cortes-Funes H, Grau JJ, García-Sáenz JA, Cruz-Hernandez JJ; Spanish Head and Neck Cancer Cooperative Group (TTCC). Phase II study of the combination of cetuximab and weekly paclitaxel in the firstline treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol. 2012;23(4):1016-22.
  • Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas D, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856-67.
  • Burtness B, Harrington KJ, Greil R, Souliéres D, Tahara M, de Castro G, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915-28.
  • Som PM, Curtin HD, Mancuso AA. An imaging- based classification for the cervical nodes designed as an adjunct to recent clinically based nodal classifications. Arch Otolaryngol Head Neck Surg. 1999; 125: 388–96.
  • Tantiwongkosi B, Yu F, Kanard A, Miller FR. Role of 18F-FDG PET/CT in pre and post treatment evaluation in head and neck carcinoma. World J Radiol. 2014; 6: 177-91
Fuente de los datos: Dialnet